Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Advisr, a US-based pre-sale workflow platform, completed a $5.2m funding round yesterday co-led by Next Frontier Capital, the venture capital firm backed by University of Montana, and Granite Capital Management. The company has now raised $7.3m altogether, it said.
Lino Biotech, a Switzerland-based focal molography technology developer, was spun out of ETH Zurich this week to commercialise its technology. The spinout has raised a seven-digit round co-led by Roche Ventures, the corporate venturing arm of pharmaceutical firm Roche that helped develop Lino’s technology, High-Tech Gründerfonds and multiple family offices. Lino’s biosensor platform will enable users to study molecular interactions in living cells and crude biosystems.
Mocean Energy, a Scotland-based wave energy technology developer, obtained £612,000 ($812,000) in a seed round backed by Old College Capital, the investment fund of University of Edinburgh, Scottish Investment and lead investor Equity Gap. The equity financing unlocked an additional $332,000 grant from Innovate UK. The company is developing two distinct versions of its wave energy technology: Blue Horizon, designed to produce grid-scale electricity, and Blue Star, created to power subsea equipment and maintenance systems.
NWEH, a UK-based clinical trials technology developer co-founded by University of Manchester, has received an undisclosed amount of funding from private investors Clive Meanwell and Chris Cox. NWEH works with consenting patients to provide electronic health records for randomised controlled trials. It was established in 2016 by the university together with Salford Clinical Commissioning Group and Salford Royal Foundation Trust.
ResBiotech, a US-based cardio-respiratory health innovation platform developer, was spun out of University of Alabama at Birmingham on Wednesday. Its first product is set to be ResBiotic, a personalised, anti-inflammatory probiotic for people suffering from respiratory illnesses. The company advances research by associate professor Charitharth Vivek Lal, who will act as chief scientific officer.
Diant Pharma, a US-based developer of continuous manufacturing technology for pharmaceutical nanoparticles, has officially licensed its technology from University of Connecticut. The spinout was founded last year, after assistant research professor Antonio Costa and distinguished professor Diane Burgess – both from the Department of Pharmaceutical Sciences – had been working on the technology since 2013. The company is now looking for partners to deploy the technology.